Physician profile
David B Cox
NPI 1174518047
$476.48
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $27.53 · 2021: $15.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $229.42 | 2019 | |
| Novo Nordisk INC | $67.42 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $53.14 | 2019 | |
| Lilly USA, LLC | $32.32 | 2019-2020 | |
| Pfizer INC. | $28.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.31 | 2019 | |
| Amgen INC. | $16.81 | 2019 | |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.88 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$148,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.